source
- Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugsLast summer, zero biotechs made it onto the public markets as the industry weathered a seven-month dry spell for initial share sales. This time around, it's a summer IPO party as sixEndpoints · 12d ago↗ source
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…Fierce Biotech · 12d ago↗ source
- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...